Agno Pharma Acquires US cGMP API Manufacturing Site

Agno Pharma, a global contract development and manufacturing organization (CDMO) specializing in small-molecule active pharmaceutical ingredients (APIs) and critical GMP intermediates, announced the acquisition of Actylis Eugene, the legacy Cascade Chemistry business based in Eugene, Oregon.

The Eugene facility, with over 20 years of small-molecule API expertise, features a 16,000 sq ft R&D laboratory and newly built 30,000 sq ft GMP manufacturing plant equipped for early- to late-phase clinical production, following substantial upgrades under prior ownership that position it for accelerated growth.

“We would like to thank Actylis for its investments and stewardship of the Eugene site, and we are extremely excited to welcome the Eugene team into the Agno Pharma platform,” said James Chen, Chief Executive Officer of Agno Pharma. “This acquisition is a transformative step forward in building a differentiated development and manufacturing hub. The Eugene site brings technical depth in early-phase API development, and its high-quality GMP infrastructure will be a powerful driver of new business as we support innovative biotech and pharmaceutical partners developing novel chemical entities.”

Agno Pharma already serves a global client base, including blue-chip pharmaceutical and biotech companies, supplying critical GMP intermediates and APIs, drug product and drug implant formulation services, as well as analytical services from preclinical through commercial phases. The acquisition of the Eugene asset meaningfully expands Agno’s manufacturing footprint and reinforces its commitment to serving its customers with onshore pharmaceutical manufacturing in the US.

Following the transaction, Agno plans to execute a disciplined and seamless integration, maintaining uninterrupted service for existing customers and accelerating investment in the site to enhance capabilities and drive long-term growth.